20S proteasome Inhibitors
1 drugsAbout 20S proteasome
The 20S proteasome is a core component of the ubiquitin-proteasome system (UPS), responsible for degrading damaged or misfolded proteins to maintain cellular homeostasis. As a barrel-shaped structure, it plays a vital role in protein turnover within cells.
The 20S proteasome is an attractive drug target, particularly in oncology, due to its fundamental role in protein turnover. Currently, there is no genetic evidence directly linking the 20S proteasome to specific diseases.
One FDA-approved drug, KYPROLIS, targets the 20S proteasome for oncology indications. This drug is a small molecule developed by ONYX PHARMS AMGEN, demonstrating the clinical viability of targeting this protein degradation machinery.
Top 20S proteasome Drugs
ONYX PHARMS AMGEN is the only company with an approved drug targeting the 20S proteasome.
Low competition suggests high market entry barriers or limited perceived opportunity, requiring careful evaluation.
20S proteasome Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets 20S proteasome, using small molecule modality.
The lack of diverse modalities represents a whitespace opportunity for novel approaches like antibodies or PROTACs.
20S proteasome Clinical Trials 215 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on 20S proteasome. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 98 | 55 | 18 | 24 | 75% |
| Phase 2 | 83 | 29 | 15 | 39 | 66% |
| Phase 3 | 30 | 10 | 2 | 18 | 83% |
| Phase 4 | 4 | 2 | 0 | 2 | 100% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Phase 3 Readout Calendar Pro
7 Phase 3 trials testing approved 20S proteasome drugs across all sponsors.
Coverage: trials whose intervention is an approved drug targeting 20S proteasome. Pre-approval candidates with development codes (e.g. AZD0901, MK-7240) are not yet linked. Anchored on CT.gov primary completion date.
20S proteasome Drug Approval Timeline (2012 - 2012)
KYPROLIS was first approved in 2012 and remains the only approved drug to date.
The lack of recent approvals indicates potential saturation or challenges in developing new 20S proteasome inhibitors.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 103 (27 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on 20S proteasome. A trial counts if an approved drug acting on 20S proteasome is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.